Get the Stockscreener App
11.62
5.06%
0.56
After Hours:
11.62
Immatics N V stock is traded at $11.62, with a volume of 421.47K.
It is up +5.06% in the last 24 hours and up +3.20% over the past month.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$11.06
Open:
$11.09
24h Volume:
421.47K
Relative Volume:
0.89
Market Cap:
$1.59B
Revenue:
$53.99M
Net Income/Loss:
$-222.30M
P/E Ratio:
-6.3966
EPS:
-1.8166
Net Cash Flow:
$-213.50M
1W Performance:
+6.90%
1M Performance:
+3.20%
6M Performance:
+13.92%
1Y Performance:
+123.46%
1-Day Range:
$11.09
$11.86
1-Week Range:
$10.18
$11.86
52-Week Range:
$4.93
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
11.62 | 1.51B | 53.99M | -222.30M | -213.50M | -1.8166 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics N.V. (IMTX) Surges 5% as Biotech Sentiment Improves; Key Resistance at $12.20 in FocusRunaway Gap - Newser
Immatics (IMTX) Surges 5%: Breaking Resistance or Facing a Ceiling?Throwback Trade - Newser
Immatics N.V. (IMTX) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Clinical ProgressVerified Analyst Reports - Newser
Immatics NV stock (NL0015255052): Q1 loss widens while cancer pipeline advances - AD HOC NEWS
How Investors May Respond To Immatics (IMTX) Wider Q1 Loss And Rising Funding Needs - simplywall.st
IMTX Maintained by Chardan Capital -- Price Target Stands at $25 - GuruFocus
Technical Reactions to IMTX Trends in Macro Strategies - Stock Traders Daily
Immatics N.V. (IMTX) Q1 2026 Earnings: Miss Sparks Concern{璐㈡姤鍓爣棰榼 - Newser
Why Is Immatics N.V. (IMTX) Stock Down Today? - Meyka
Immatics N.V. (IMTX) Q1 2026 Results Fall Short — EPS $-0.43, Revenue $N/A{璐㈡姤鍓爣棰榼 - Newser
Immatics NV stock (NL0015255052): T. Rowe Price discloses 16.1% stake – what it means for investor - AD HOC NEWS
[SCHEDULE 13G/A] Immatics N.V. Amended Passive Investment Disclosure - Stock Titan
TD Bank (IMTX) discloses 7.44M shares, 5.5% stake (Schedule 13G) - Stock Titan
T. Rowe Price reports 16.1% stake in IMMATICS (NASDAQ: IMTX) - Stock Titan
Immatics N.V. (IMTX): RTW reports 12.87M shares, 9.6% stake - Stock Titan
Immatics N.V. (NASDAQ:IMTX) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results - Yahoo Finance
TradingKey - TradingKey
What Immatics (IMTX)'s Heavier PRAME R&D Spending and 2026 Milestones Mean For Shareholders - Sahm
Immatics NV earnings missed by €0.04, revenue fell short of estimates - Investing.com Australia
Immatics Releases Q1 2026 Financial Results - AlphaStreet
Immatics (IMTX) Reports Q1 Revenue as It Prepares for Future Gro - GuruFocus
Immatics NV stock (NL0015255052): Q1 2026 loss widens to €57.8m - AD HOC NEWS
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Immatics Widens Q1 2026 Loss as Collaboration Revenue Drops, R&D Spend Climbs - TipRanks
Immatics Q1 Loss Widens, Revenue Falls - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q1 Revenue 7.6M Euros, vs. FactSet Est of 8.5M Euros - marketscreener.com
Earnings Flash (IMTX) Immatics Posts Q1 Net Loss 0.43 Euro a Share, vs. FactSet Est of 0.45 Euro Loss - marketscreener.com
Immatics: Q1 Earnings Snapshot - standard-journal.com
Immatics Announces First Quarter 2026 Financial Results and Business Update - The Manila Times
Immatics (NASDAQ: IMTX) deepens Q1 2026 loss but keeps cash runway into 2028 - Stock Titan
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Melanoma cell therapy targets 2027 debut as Immatics posts $66.5M Q1 loss - Stock Titan
Number of shareholders of Immatics N.V. – TRADEGATE:4A3 - TradingView
Trading the Move, Not the Narrative: (IMTX) Edition - Stock Traders Daily
Immatics N.V. (IMTX) Stock Analysis: Potential 68% Upside Amid Strategic Collaborations and Innovative Cancer Therapies - DirectorsTalk Interviews
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy - sharewise.com
Immatics (IMTX) to Release Quarterly Earnings on Tuesday - MarketBeat
TD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendation - MSN
Immatics (NASDAQ:IMTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Immatics NV Stock Operating Data - GuruFocus
Immatics NV (HAM:4A3) Cyclically Adjusted PS Ratio : (As of May. 01, 2026) - GuruFocus
Immatics NV (HAM:4A3) Stock News, Headlines & Updates - GuruFocus
Operating cash flow per share of Immatics N.V. – MUN:4A3 - TradingView
Net current asset value per share of Immatics N.V. – MUN:4A3 - TradingView
IMTX Initiates Coverage On TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Immatics stock coverage with buy rating By Investing.com - Investing.com India
TD Cowen initiates Immatics stock coverage with buy rating - Investing.com
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):